Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Director Luca Benatti purchased 1,200 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was bought at an average price of $83.50 per share, with a total value of $100,200.00. Following the purchase, the director now owns 7,556 shares of the company’s stock, valued at approximately $630,926. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of ICPT opened at $86.75 on Thursday. Intercept Pharmaceuticals Inc has a 1 year low of $65.63 and a 1 year high of $133.74. The firm has a market cap of $2.49 billion, a PE ratio of -7.99 and a beta of 1.49. The company has a debt-to-equity ratio of 19.41, a current ratio of 3.72 and a quick ratio of 3.72.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($3.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.57) by ($0.46). Intercept Pharmaceuticals had a negative net margin of 162.49% and a negative return on equity of 617.23%. The firm had revenue of $52.25 million for the quarter, compared to analyst estimates of $52.15 million. During the same period last year, the firm posted ($3.22) EPS. The business’s revenue was up 45.3% compared to the same quarter last year. On average, analysts anticipate that Intercept Pharmaceuticals Inc will post -9.56 earnings per share for the current year.

ICPT has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 16th. UBS Group initiated coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday, January 23rd. They issued a “buy” rating and a $130.00 price target for the company. Needham & Company LLC upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research note on Thursday, January 24th. Jefferies Financial Group lifted their price target on shares of Intercept Pharmaceuticals to $150.00 and gave the stock a “buy” rating in a research note on Monday, January 28th. Finally, JMP Securities upgraded shares of Intercept Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $75.00 to $175.00 in a research note on Wednesday, January 30th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and seventeen have assigned a buy rating to the company. Intercept Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $145.67.

Institutional investors and hedge funds have recently made changes to their positions in the company. Financial Gravity Wealth Inc. acquired a new position in shares of Intercept Pharmaceuticals during the first quarter valued at $33,000. Intercontinental Wealth Advisors LLC acquired a new position in shares of Intercept Pharmaceuticals during the fourth quarter valued at $34,000. Coastal Investment Advisors Inc. acquired a new position in shares of Intercept Pharmaceuticals during the first quarter valued at $70,000. Advisor Group Inc. boosted its holdings in shares of Intercept Pharmaceuticals by 63.5% during the fourth quarter. Advisor Group Inc. now owns 739 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 287 shares during the period. Finally, Botty Investors LLC acquired a new position in shares of Intercept Pharmaceuticals during the first quarter valued at $84,000. 68.38% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://theolympiareport.com/2019/05/16/luca-benatti-buys-1200-shares-of-intercept-pharmaceuticals-inc-icpt-stock.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Recommended Story: Why is a lock-up period needed for an IPO?

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.